Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2009 June;34(2) > Minerva Endocrinologica 2009 June;34(2):195-202

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

REVIEWS  


Minerva Endocrinologica 2009 June;34(2):195-202

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Male osteoporosis

Rocchietti March M., Pisani D., Aliberti G.

Department of Internal Medicine Sant’Andrea Hospital, Rome, Italy II Faculty of Medicine and Surgery University of Rome “La Sapienza”, Rome, Italy


PDF  


Osteoporosis is a worldwide major public health problem, defined as “a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fractures”. Osteoporosis is diagnosed by bone mineral density measurement (T-score of -2.5 or below) also in men. However, most of the studies carried out in the last decade focused on pathogenesis, diagnosis and treatment of osteoporosis in women. In spite of this, recent epidemiological and observational studies have shown that osteoporosis in men is an increasingly important clinical issue. In part because the world population is aging, it is likely that the total number of hip fractures in men in 2025 will be similar to current estimates in women. Furthermore 25-33% of men in some populations will sustain osteoporotic fractures in their lifetime. Nevertheless, male osteoporosis is still underdiagnosed and further studies are required to clarify the pathogenesis and find out the right therapy. Prevention and early diagnosis are, nowadays, the best ways of treatment.

top of page

Publication History

Cite this article as

Corresponding author e-mail